UHS Falls 4.5% on Q3 Day as Call Euphoria Unwinds

Universal Health Services has delivered its Q3 results and the market's verdict was swift: the bullish options positioning that dominated the lead-up to earnings has collapsed, replaced by a 4.5% drop on the day to $177.32 and a reset in sentiment across the board.

The reversal in options is the sharpest visible change from the pre-earnings notes. Three weeks ago the put/call ratio was at its 52-week low of 0.31, more than two standard deviations below its 20-day average. That call-dominated setup has since unwound. The PCR now reads 0.38, still marginally below the 20-day mean of 0.45, but the direction has flipped. Call demand dominated for much of October. It is no longer doing so. Retail attention has also spiked, with Wikipedia page views running 2.7 standard deviations above UHS's own 90-day average as of October 21, a sign that the price drop has drawn a wider audience than usual.

Short positioning is a secondary story, but it has moved in a consistent direction. Shares short rose 3% on the week to 4.8% of the free float, continuing a grind higher after a sharper pullback in mid-October. That is a modest level and the borrow market remains loose, with availability at 848% of short interest and borrowing costs at 0.43%. Nothing in the lending data suggests a crowded or technically stressed short base. The ORTEX short score sits at 43.7, near the middle of its range, consistent with low conviction from either side.

The Street was already cautious before the print. The consensus is a hold, and the trajectory of analyst moves since July tells a clear story: Goldman Sachs cut its target from $242 to $190, Morgan Stanley from $212 to $191, and RBC from $190 to $183, all while keeping neutral or equivalent ratings. The mean target has settled around $196, implying roughly 10% upside from the current price. The bull case rests on behavioral health, which generates over half of operating income, and on capacity expansion and state directed payment programs. Bears point to sluggish acute care volumes, geographic concentration in Nevada, Texas and California, and the risk that state budget pressure crimps the more profitable behavioral health segment. Valuation has compressed: the EV/EBITDA multiple has dropped roughly 0.18 turns on the week to 5.8x, and the P/E ratio has pulled back to 7.5x. The earnings yield factor score ranks in the 94th percentile and EV/EBIT in the 90th, making UHS look statistically cheap. EPS momentum scores, at the 30th percentile over 30 days and 24th over 90 days, tell a less reassuring story about where estimates are headed.

Peers moved lower on the day too, though less severely. HCA fell 3.3% and THC dropped 2.6%, suggesting sector-wide pressure rather than a purely company-specific selloff. SGRY was the exception, up 0.5% on the day and 51% on the week, though its correlation to UHS is low enough to make that a different story entirely.

Two fresh 13G filings are worth noting. Dimensional Fund Advisors crossed 5% on October 8 and Pzena Investment Management filed its own 13G on October 19, also at 5.1%. Both are passive filings. As always with 13D/G disclosures, these are event-driven around the 5% threshold and positions may have moved since. Still, two new passive holders crossing the reporting line in the same month is incremental support data, even if neither changes the fundamental picture.

With Q3 now in the market and the next event scheduled for late February 2027, the debate shifts to whether the post-print selloff has created a valuation entry point or whether deteriorating EPS momentum justifies the multiple compression.